Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252641 | 0.88 | KDM4E (0.73) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL5239218 | 0.88 | KDM4E (0.73) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL10670286 | 0.87 | MTNR1A (0.71) | KDM4EMTNR1AMTNR1BHTR2BCYP1A2 | |
| SCHEMBL1395687 | 0.85 | KDM4E (0.77) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL2686551 | 0.85 | KDM4E (0.77) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| Hydrochloric Acid SCHEMBL5013119 | 0.84 | KDM4E (0.75) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL674415 | 0.83 | KDM4E (1.00) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL2633259 | 0.83 | KDM4E (0.79) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL14664126 | 0.83 | KDM4E (0.73) | KDM4EMTNR1AMTNR1BHTR2BGPR84 | |
| SCHEMBL6945002 | 0.82 | KDM4E (0.77) | KDM4EMTNR1AMTNR1BHTR2BGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337535-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-06-09 | — | — | EP | disclosed |
| US-6743789-B2 | SUBSTITUTED IMIDAZO (1,5-A) (1,2,4) TRIAZOLO (4,3-D) (1,4) BENZODIAZEPINE DERIVATIVES ARE USEFUL FOR TREATING ALZHEIMER'S DISEASE; REACTING A BEZODIAZEPINE DERIVATIVE WITH A HYDRAZIDE DERIVATIVE TO FORM END PRODUCT | HOFFMANN-LA ROCHE INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1337535-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | KDM4E 1588/4885MTNR1A 96/4885MTNR1B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.